Journal
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Volume 42, Issue 12, Pages 1221-1224Publisher
WILEY-BLACKWELL
DOI: 10.1111/1440-1681.12478
Keywords
cardiovascular disease; platelet-derived growth factor
Categories
Funding
- Natural Science Foundation of China [91339117]
- Hong Kong Research Grants Council [CUHK2/CRF/12G]
- Chinese University of Hong Kong
Ask authors/readers for more resources
Over 40 years of studies on platelet-derived growth factors (PDGFs) and their receptors, the molecular mechanisms and functional roles of PDGFs in the development of embryos and human diseases, especially in cancer, are gradually being unravelled. PDGF-BB was approved by the United States Food and Drug Administration for promoting wound healing, while imatinib, which selectively inhibits tyrosine kinase activity of PDGF receptors (PDGFR), has been prescribed to treat patients with gastrointestinal stromal tumor and chronic eosinophilic leukaemia. However, much less often have these drugs been studied in relation to cardiovascular diseases. This brief review mainly describes the role of PDGF signalling in cardiovascular pathogenesis such as atherosclerosis, pulmonary arterial hypertension, diabetes, angiogenesis and inflammation with an emphasis on how PDGFs function in these situations and what components might serve as potential therapeutic targets against cardio-metabolic dysfunction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available